id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-023963-8hede7cz	Nowak-Wegrzyn, Anna	Food allergy 2020: learning from the past, looking to the future	2020-04-23		.txt	text/plain	1199	78	53	At the end of January 2020, the US Food and Drug Administration issued approval for the first drug for peanut oral immunotherapy (OIT), giving hope to many 4-to 17-year old children with peanut allergy and their caregivers. Should the diagnosis of peanut allergy be confirmed with an oral food challenge before initiating OIT? Capucilli et al 2 performed a comprehensive PubMed literature search of reviews and clinical articles discussing peanut or other food-related allergic reactions, accidental exposures, or anaphylaxis pertinent to avoidance diet or comparative with OIT trials. They concluded that considering the increased risk of anaphylaxis during the first year of OIT, peanut avoidance remains a viable option for long-term peanut allergy management and should be discussed with all patients with food allergy seeking novel therapies. They postulate this as an important area for future research to gain better accuracy in predicting patients at the highest risk of severe food-induced anaphylaxis.	./cache/cord-023963-8hede7cz.txt	./txt/cord-023963-8hede7cz.txt